The Goldman Sachs Group downgraded shares of HUTCHMED (NASDAQ:HCM) from a buy rating to a neutral rating in a research report released on Wednesday, Analyst Price Targets reports. The Goldman Sachs Group currently has $46.00 price target on the stock.
Several other analysts have also recently weighed in on HCM. Cantor Fitzgerald raised their price target on HUTCHMED from $40.00 to $45.00 and gave the company an overweight rating in a report on Tuesday, July 13th. Zacks Investment Research raised HUTCHMED from a sell rating to a hold rating in a report on Tuesday, September 14th. Finally, Jefferies Financial Group started coverage on HUTCHMED in a research note on Tuesday, August 3rd. They issued a buy rating and a $52.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, HUTCHMED has an average rating of Buy and a consensus price target of $44.60.
NASDAQ HCM opened at $36.56 on Wednesday. HUTCHMED has a 12-month low of $23.67 and a 12-month high of $43.94. The firm’s 50 day moving average is $39.91 and its 200-day moving average is $33.44. The company has a quick ratio of 4.30, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $6.32 billion, a PE ratio of -40.62 and a beta of 1.08.
HUTCHMED Company Profile
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.